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Deletions of 17p13.3, including the LIS1 gene, result in the brain malformation lissencephaly, which is characterized
by reduced gyration and cortical thickening; however, the phenotype can vary from isolated lissencephaly sequence
(ILS) to Miller-Dieker syndrome (MDS). At the clinical level, these two phenotypes can be differentiated by the
presence of significant dysmorphic facial features and a more severe grade of lissencephaly in MDS. Previous work
has suggested that children with MDS have a larger deletion than those with ILS, but the precise boundaries of
the MDS critical region and causative genes other than LIS1 have never been fully determined. We have completed
a physical and transcriptional map of the 17p13.3 region from LIS1 to the telomere. Using fluorescence in situ
hybridization, we have mapped the deletion size in 19 children with ILS, 11 children with MDS, and 4 children
with 17p13.3 deletions not involving LIS1. We show that the critical region that differentiates ILS from MDS at
the molecular level can be reduced to 400 kb. Using somatic cell hybrids from selected patients, we have identified
eight genes that are consistently deleted in patients classified as having MDS. In addition, deletion of the genes
CRK and 14-3-3 delineates patients with the most severe lissencephaly grade. On the basis of recent functional
data and the creation of a mouse model suggesting a role for 14-3-3 in cortical development, we suggest that
deletion of one or both of these genes in combination with deletion of LIS1 may contribute to the more severe
form of lissencephaly seen only in patients with MDS.
Introduction
Classical lissencephaly (LIS) is a severe brain malfor-
mation characterized by absent or reduced gyration of
the cerebral surface and a thickened and simplified four-
layered cortex resulting from incomplete neuronal mi-
gration during early brain development. Patients with
LIS usually have mental retardation, intractable epilepsy,
spasticity, and reduced longevity (Dobyns et al. 1993).
The clinical severity generally correlates with the degree
of agyria and cortical thickening. The complete LIS spec-
trum includes agyria (LIS grade 1), mixed agyria-pach-
ygyria (LIS grades 2 and 3), and pachygyria alone (LIS
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grade 4) (Dobyns et al. 1999). The genetic basis of LIS
has now been elucidated for most patients, with two
main patterns evident. LIS more severe posteriorly than
anteriorly is generally secondary to abnormalities of the
LIS1 gene (PAFAH1B1 [MIM 601545]) on 17p13.3.
This form of LIS is seen in both isolated lissencephaly
sequence (ILS) andMiller-Dieker syndrome (MDS [MIM
247200]). LIS more severe anteriorly than posteriorly is
generally due to abnormalities of the DCX gene (or
doublecortin [MIM 300121]) on Xq22.3–q23 (Pilz et
al. 1998a).
ILS is characterized by LIS and minimal or no other
dysmorphic features. MDS is associated with LIS, sig-
nificant facial dysmorphism, and, occasionally, other
congenital anomalies, such as renal, gastrointestinal,
and cardiac defects (table 1). In addition, the severity
of LIS seen in MDS is generally greater than that seen
in ILS (Dobyns et al. 1991). MDS is seen only in patients
with deletions of 17p13.3, detected either by high-res-
olution cytogenetics or by the use of specific FISH
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Table 1
Clinical Manifestations Observed in Patients with ILS versus Patients with MDS
AFFECTED
REGION
MANIFESTATION IN PATIENTS WITH
ILS MDS
Brain Grade 2–4 LIS Grade 1 LIS
Face Bitemporal hollowing, mildly small jaw Bitemporal hollowing, small jaw, microcephaly, tall square forehead,
vertical forehead furrow, flattened midface, short upturned nose,
thickened rounded upper lip, low-set posteriorly rotated ears,
frontal bossing, prominent lateral nasal folds
Other None Cardiac defects, omphalocele, inguinal hernia, duodenal atresia,
cryptorchidism, cystic kidney, pelvic kidney, polydatctyly, clino-
dactyly, campylodactyly, transverse palmar creases
probes (Ledbetter et al. 1989; Pilz et al. 1998b). In con-
trast, ILS may be secondary to deletions of 17p13.3,
intragenic mutations, or internal deletions of the LIS1
gene (Chong et al. 1997; Lo Nigro et al. 1997).
The precise deletion boundaries and, therefore, the
deleted genes differentiating ILS from MDS in patients
with 17p13.3 deletions have never been adequately de-
termined. Previous studies have shown that the telo-
meric border of 17p13.3 deletions in MDS is generally
more distal than those in patients with ILS (Chong et
al. 1996). The study of patients with MDS and ILS also
raises the question as to why patients with MDS have
more severe LIS than patients with ILS. It may be as-
sumed that the differences between the ILS and MDS
phenotypes (namely, the severity of LIS and the dys-
morphic features) must be secondary to deletion of ad-
ditional genes telomeric to LIS1. Haploinsufficiency of
the LIS1 gene alone is insufficient to explain the severe
(grade 1) LIS seen only in MDS patients. This suggests
that there are cortical development genes other than
LIS1 deleted in patients with MDS but not in those
with ILS.
The aim of this study was to investigate the genotypic
difference between patients with MDS and ILS second-
ary to 17p13.3 deletions and to use this data to identify
candidate genes to explain the difference in the phe-
notype. We initially performed a detailed phenotypic
characterization of 34 patients with a deletion of
17p13.3, including 4 patients without LIS. We con-
structed a physical and transcriptional map covering the
most distal 2.8 Mb of the 17p13.3 region. We used
BAC/PAC genomic clones in FISH experiments to size
the deletions in a spectrum of MDS and ILS patients,
which defined the telomeric critical region for MDS dis-
tal to D17S1574. In addition, we mapped the 17p13.3
deletion in the four patients without LIS and mild or
no dysmorphic features, to refine this region to 400 kb.
Within this “telomeric MDS critical region,” we used
PCR analysis of somatic cell hybrids from patients with
ILS and MDS to identify two candidates genes among
eight, which, when deleted together with LIS1, could
be responsible for the more severe cortical phenotype
seen in MDS.
Subjects and Methods
Patient Ascertainment
Subjects were ascertained through the Lissencephaly
Research Project, which currently is based at The Uni-
versity of Chicago, from referrals from physicians and
genetic counselors, The Lissencephaly Network, and in-
quiry from parents of affected children. We reviewed
clinical data in all 34 patients and cranial computed
tomography or magnetic resonance imaging scans in 27
of 30 patients with LIS and 2 of 4 patients without LIS.
If the child could not be examined, photographs were
used to document the facial phenotype.
Clinical Ascertainment and Diagnosis
We selected 30 patients with ILS or MDS for study.
All came to medical attention because of problems, in-
cluding abnormal appearance, feeding problems, devel-
opmental delay, seizures, or a combination of these. All
had LIS on brain imaging, and all had deletions of
17p13.3 by high-resolution cytogenetics or FISH. De-
letions were visible in 9 of 30 patients, including 2 pa-
tients (LP90-007 and LP95-041) with unbalanced seg-
regation of familial translocations involving chromo-
some 17p and 16p or 3p. Brain imaging studies were
available for 27 of the 30 patients and were reviewed
to confirm the diagnosis of ILS or MDS. Evaluation was
performed by use of an LIS grading scale described else-
where (Dobyns et al. 1999).
We also studied four unrelated subjects with a deletion
of the 17p13.3 region but without LIS. Of these subjects,
two (96.583 and 97.513) had a telomeric 17p deletion
identified by cytogenetic analysis (Martin et al. 2002).
The other two subjects carried a deletion of the 17p13.3
region due to an unbalanced translocation between 17p
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Table 2
Primer Pairs Used to Amplify Genes Localized in the Telomeric MDS Critical Region
Gene
Forward Primer
(5′r3′)
Reverse Primer
(5′r3′)
ABR exon 1 GCAGTGGCTCCTTGATACAAA AACACTATGGGCTCCACTGAG
14-3-3 exon 6 TGGCTGCCATAGCCTAATGTA TCAGTGACAATGGGGAGTTTC
CRK exon 2 CAGACTCCGAATAGGAGATCA CCAAAGCCAAGGCTGTCTTGT
CRK exon 3 TAGTGGTCGTGCCTGTGTGTA AACAGTCTGTCGCCATTTGAT
MYO1C exon 2/3 GACACTGTGTACCGAGCACTG AGCACCGGGTTGCTCTGTAG
SKIP exon 9 CATCCTGTGGAGGCTGAAG TACGTCATGTGGCTGCTGTAG
PITPNa 3′ UTR AGTGGTCAACAGGAAGACCC AATGGATCGGAACACAATGG
SREC 3′ UTR AAGGCAGGAGGAACCTGAGTA CAGGACAGCAGAGCAAAAGTC
RILP exon 6 AGAGGGACAGTACAAAGGGTTG CATCAGGCTCAGCAGAATGAG
PRP8 exon 41/43 CAAGATCATGGCTGACAACC CAAACTGCTGAATGTCAGCG
SERPINF1 exon 5 TTGACCGGAAGCATGAGTATC GGTGACTTCGCCTTCGTAACT
RPA1 3′ UTR CATCGGTAGGCAAAGGAAAA ACAGAAGCCTGAAGGCAGAG
LIS1 exon 2 CATTACAGCCAAGATGGTGCT AGCACCATCTTGGCTGTAATG
and 8p (patient DR00-063a1) or between 17p and 5p
(patient DR01-001) (Mutchinick et al. 1999).
We examined 22 of the 30 patients with LIS and re-
viewed photographs of all but 1. We also examined and
reviewed photographs of patients DR00-063a1 and
DR01-001. We used a simple facial malformation grad-
ing system, in which facial changes were graded as nor-
mal (0), intermediate (1), or typical of MDS (2) by each
of three experienced clinical geneticists (J.A., D.T.P., and
W.B.D.). The three examiner scores were added together,
giving overall scores of 0–6. Patients with scores of 0–2
were classified as having a normal facial appearance
(ILS), patients with scores of 3–5 as having intermediate
facial changes (ILS), and patients with a score of 6 as
having severe and characteristic facial abnormalities
(MDS).
Identification and Characterization of BAC and P1-
Derived Artificial Chromosomes (PAC)
Thirteen BAC clones from the RPCI-11 human library,
nine BAC clones from Caltech human libraries B and
D, and five PAC clones from RPCI-4 and -5 human
libraries were selected to cover the most distal 3 Mb of
chromosome 17p13.3, which corresponds to the pre-
sumed telomeric critical region for MDS. The vast ma-
jority of the clones were selected from human chro-
mosome 17 database resources, such as the Sanger
Institute and the Weizmann Institute, as well as genome
resources, such as the National Center for Biotechnology
Information (NCBI), for their content of STSs, ESTs, or
genes described previously in the 17p13.3 region (Stack
et al. 1995; Plummer et al. 1997; Hoff et al. 2000;
McHale et al. 2000). All genomic clones were purchased
from Research Genetics. Genomic DNA from BAC and
PAC clones was isolated by use of an automated DNA
isolation system (AutoGen 740, Integrated Separation
Systems). The BACs and PACs were further character-
ized by PCR to analyze the presence or absence of
STSs and by FISH to confirm their cytogenetic positions.
Two clones, PAC95H6 and RPCI5-59D14 (GenBank
AC006435), were selected on the basis of published
physical and transcriptional maps of 17p13.3 (Chong et
al. 1997; McHale et al. 2000), and GSS-68F18 was se-
lected as a telomeric probe (Knight et al. 2000).
In Silico Identification and Mapping of STSs and ESTs
For our BAC/PAC contig, the complete or unfinished
sequence for all the clones was available from the NCBI
databases. We systematically analyzed these sequences
to identify and map STSs and new ESTs or to confirm
the mapping of known genes, using the NIX genomic
sequence analysis program and the BLASTN algorithm
using the NCBI databases against STS or EST databases.
STS and Gene Mapping by PCR
PCR reactions were carried out in a total volume of
50 ml containing 25–50 ng of DNA as the template, 1#
PCR buffer with 1.5 mMMgCl2, 0.2 mM of each dNTP,
1 mM of each primer, and 2.5 U TaqGold polymerase
(PE Applied Biosystems). Amplifications were performed
in a PE480 thermal cycler (Perkin Elmer-ABI), with a 5-
min 94C denaturation step followed by 35 cycles of
94C for 35 s, 35 s of annealing at the appropriate tem-
perature, and 40 s of elongation at 72C. The last cycle
was followed by a final extension at 72C for 10 min.
PCR products were separated on 2% agarose gels.
Primer sequences and annealing temperatures for the
previously assigned STSs were obtained by use of the
CEPH-Ge´ne´thon database, the Whitehead/MIT Center
for Genome Research database, the NCBI UniSTS da-
tabase, and the HUGOGenome database (GDB), as well
as data published elsewhere (Hoff et al. 2000; McHale
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et al. 2000). The primer pairs used to amplify all genes
localized between D17S1574 and D17S1840 are listed
in table 2.
FISH Analyses
Slide, probe preparation, and hybridization were com-
pleted using methods described elsewhere (Chong et al.
1997). For three-color FISH experiments, probes were
directly labeled with DEAC (Diethylaminocoumarin-5-
dUTP, Perkin Elmer Life Sciences), Spectrum Orange-
dUTP, and Spectrum Green-dUTP (Vysis). The DEAC
probe signals were pseudocolored with magenta, be-
cause of the color similarities between DEAC and DAPI.
FISH slides were analyzed by use of a Zeiss Axiophot
microscope with single pass filters (Chroma Technol-
ogy). Images were collected using a CCD camera (Nu
200, Roper Scientific) and Smart Capture 2 software
program (Digital Scientific).
Somatic Cell Hybrids
Somatic cell hybrids containing deletions of the
17p13.3 region were derived from two MDS patients
(hybrid cell lines CA2 and KCB4 from patients LP82-
002 and LP84-001, respectively) and from three ILS pa-
tients (hybrid lines DB, BR8, and SG2 from patients
LP86-003, LP87-001, and LP90-017, respectively) and
have been described elsewhere (Van Tuinen et al. 1987;
Ledbetter et al. 1989; Ledbetter et al. 1992). DNA was
extracted from somatic cell hybrids by use of a Puregene
DNA isolation kit (Gentra Systems), according to the
manufacturer’s protocol. We ensured that the primers
were human specific by using total genomic DNA from
mouse and hamster as a negative control.
Results
Detailed Phenotypic Analysis of 34 Selected Patients
To establish a strong genotype-phenotype correlation
between patients with deletions of 17p13.3, we per-
formed a detailed phenotypic analysis on 34 selected
patients (see the “Subjects and Methods” section).
Among the 34 patients, by comparison with normal
MRI images (fig. 1I and 1J), 30 patients had LIS and 4
had no LIS. Of the 30 patients with LIS, 10 had con-
sensus ILS with a normal facial appearance, except for
the minor changes typical of this condition (table 1; fig.
1A); 9 patients had intermediate facial abnormalities and
were classified as ILS (fig. 1C); and 11 had a consensus
MDS facial appearance (table 1 and fig. 1E and 1G).
Patients with ILS always had LIS grade 3 or 4 (fig. 1B),
whereas those with ILS had LIS grade 2 or 3 (fig. 1D).
In contrast, all patients with consensus MDS had LIS
grade 1 or diffuse agyria (fig. 1F and 1H) and the char-
acteristic facial features (table 1). Thus, we found a
strong correlation between the most prominent dys-
morphic features and most severe brain abnormalities.
Of the four subjects who did not have LIS, two
(96.583 and 97.513) were phenotypically normal (Mar-
tin et al. 2002), and the other two (DR00-063a1 and
DR01-001) were mentally retarded. Regarding the latter,
DR00-063a1 had a normal MRI scan, and DR01-001
had epilepsy and microcephaly, with anMRI scan show-
ing a thin corpus callosum and frontal lobe hypoplasia
(fig. 1L). DR01-001 had mild facial dysmorphism and
has been reported elsewhere (Mutchinick et al. 1999) as
having a facial phenotype consistent withMDS (fig. 1K).
On consensus review for this study, we concluded that
she had an abnormal facial appearance that did not meet
our criteria for typical MDS.
Physical and Transcriptional Map from D17S1845 to
the 17p Telomere
To identify which telomeric genes could participate
with LIS1 in producing the more severe phenotype seen
in MDS, compared to that in ILS, we constructed a phys-
ical and transcriptional map from the proximal marker
D17S1845 (close to LIS1) toward the telomere. A BAC/
PAC contig was created by linking newly characterized
BAC and PAC clones obtained from numerous databases
with data published elsewhere (see the “Subjects and
Methods” section). We used an STS-based approach
combined with computational methods to construct a
BAC/PAC contig spanning ∼2.8 Mb (fig. 2). Each BAC
or PAC clone was tested by FISH analysis on normal
human metaphase chromosomes to verify its unique lo-
calization to 17p13.3. BAC407I21 (GenBank accession
number AF322450), for which sequence is available at
the NCBI database, was previously mapped on 17p13.3
by Gu and colleagues (Shanghai Cancer Institute).
The completed contig consists of 23 BAC and 6 PAC
clones (fig. 2). It includes three regions covered only
by a single BAC clone, which corresponds to the
clones RPCI-11 135N5 (GenBank accession number
AC015799), RPCI-11 676J12 (GenBank AC087392),
and RPCI-11 818O24 (GenBank AC032044). For the
latter region, the CRK gene (GenBank NM_005206 and
NM_016823) helped us to link the clone RPCI11-
818O24 with BAC407I21. The overlap between these
two BACs, not previously identified as being overlapping
clones, corresponds to exon 2 and intron 2 of the highly
conserved CRK gene, which we estimate to be at least
12 kb by comparison with the mouse genome sequence
(cf. clone RPCI23-78H4 [GenBank AL669897] and
clone RPCI23-190H20 [GenBank AL663094]). In ad-
dition, the telomeric minicontig could not be joined with
the main contig (fig. 2). On the basis of the size esti-
mation of this region by the Weizmann Institute data-
base, we expect that the gap between PAC RPCI5-
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1029F21 (GenBank AC015853) and BAC CTD-2578J3
(GenBank AC108006) is no more than 150 kb in length.
Using the physical clone contig as a resource, we as-
signed 23 known genes, 11 ESTs or unknown genes, and
1 pseudogene to17p13.3, all of which were described in
the Unigene database. We also assigned 24 genetic mark-
ers or anonymous STSs and 15 BAC/PAC end clones to
this region (fig. 2).
Characterization of the “Telomeric Critical Region for
MDS”
To further define the “telomeric MDS critical region,”
we used a selection of BAC/PAC clones from our map
as probes (fig. 2, clones noted in red) for FISH analysis
to size and determine the boundaries of the deletion in
our 34 selected patients (fig. 3). In addition, we used
two BACs centromeric to D17S1845 as controls:
RPCI11-713H12 (AC025518) contains the NUDEL
gene (NM_030808), which interacts with LIS1 (Sasaki
et al. 2000), and was not deleted in any of the 34 patients
(fig. 3). Probe RPCI11-305G1 (AC032038) contains the
profilin1 gene (NM_005022) and was deleted in only 4
of 34 patients (fig. 3). For one patient with MDS (LP84-
001), PAC95H6 showed partial deletion of the LIS1
gene (fig. 3), which was confirmed by deletion of the
telomeric overlapping clone RCPI11-135N5, which con-
tains exons 1 and 2 of the LIS1 gene (data not shown).
Comparing the size of the deletions identified in patients
with MDS with the size of the deletions in patients with
ILS  and ILS, we found that BAC RPCI11-107N19
(AC006405) was deleted in three patients with ILS
(LR01-118, LP99-086, and LP86-003) and all patients
with MDS (fig. 3). Next, we compared the size of the
deletion among patients with MDS and found that, for
one MDS patient (LP82-002), the deletion did not ex-
tend beyond BAC RPCI11-818O24 (figs. 2 and 3).
Therefore, our FISH studies demonstrated that the
“telomeric critical region for MDS” is contained
within the two BACs RPCI11-107N19 and RPCI11-
818O24, which means that the critical region is distal
to D17S1574, which is contained in RPCI11-4F24
(AC007873), and proximal to D17S1582, which is lo-
cated at the telomeric end of RPCI11-818O24 (figs. 2
and 3).
This result is also supported by sizing of the deletion
in the four subjects who did not have LIS. For the two
phenotypically normal individuals (96.583 and 97.513),
FISH analysis revealed a deletion of the 17p telomeric
region, which for 97.513 included the ABR gene (fig.
3). Our data confirmed the previous cytogenetic analysis
(Martin et al. 2002), which revealed satellites on the
short arm of one chromosome 17 and indicated that the
most distal genes are not dosage sensitive. Next, we
mapped the breakpoint on the deleted chromosome 17
of the two mentally retarded patients (see the “Subjects
and Methods” section) as being around marker SHGC-
32238 for patient DR00-063a1 and D17S1574 for
DR01-001 (figs. 2 and 3). DR00-063a1, with the small-
est deletion, had mild mental retardation and normal
facial appearance, as did her mother (data not shown).
DR00-001, with the largest deletion, had severe mental
retardation and mild facial dysmorphism not considered
typical of MDS (fig. 1K and 1L). However, patient
DR01-001 also has several specific phenotypic traits
characteristic of the 5p trisomy due to significant ad-
ditional material added to the deleted 17p as a result of
the translocation with 5p. Specific phenotypic charac-
teristics of the trisomy 5p present in patient DR01-001
are a depressed nasal bridge, long fingers, and bilateral
talipes equinovarus (Mutchinick et al., 1999). In these
two patients, we identified a region that may contain a
gene involved or responsible for mental retardation,
which seems to overlap with the “telomeric critical re-
gion for MDS” previously defined.
Finally, this data has enabled us to design a three-
color FISH assay using PAC95H6, BAC RPCI11-
818O24, and BAC68F18 (fig. 3) as a diagnostic screen
for patients with 17p13.3 deletions, and the results
showed a robust correlation with the clinical phenotype
(fig. 4). Deletion of PAC 95H6 alone (fig. 4B) was as-
sociated with ILS (fig. 1C and 1D). Deletion of
PAC95H6 in combination with one or both of RPCI11-
818O24 or BAC68F18 (fig. 4C) was associated with
MDS (fig. 1G and 1H). Deletion of RPCI11-818O24
and BAC68F18 but not PAC95H6 (fig. 4D) was not
associated with a LIS phenotype (fig. 1K and 1L).
Deletion of CRK and 14-3-3 Is Seen Only in Patients
with the Most Severe Form of LIS
With the telomeric MDS critical region defined, we
wanted to determine which genes within that region (in
addition to LIS1) may contribute to theMDS phenotype
when deleted. We used somatic cell hybrids established
from five selected patients with LIS and deletions in-
volving the telomeric MDS critical region. Among these
five patients, three had an intermediate ILS phenotype
with mild dysmorphic features and grade 3 LIS for SG2
(LP90-017) or grade 2 LIS for BR8 (LP87-001) and DB
(LP86-003). The two others, CA2 (LP82-002) andKCB4
(LP84-001) had a consensus MDS phenotype with dis-
tinct dysmorphic features and grade 1 LIS (fig. 3).
By PCR, we tested all known genes in the telomeric
MDS critical region between D17S1574 and D17S1582
(fig. 2 and table 2) (see the “Subjects and Methods”
section). PCR results showed that, for hybrid SG2, am-
plification of the PRP8 gene (GenBank XM_028335)
delineated a telomeric deletion boundary around the STS
marker SHGC-32238 (figs. 2 and 5). For hybrids BR8
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Figure 1 Detailed phenotypic analysis of patients with deletions of 17p13.3, showing increasing severity of brain and face changes with
larger deletions extending closer to the 17p telomere. LP95-108 has typical ILS with normal facial appearance (A) and LIS grade 3 with a
posterior 1 anterior gradient (B) associated with a small submicroscopic deletion. LP99-086 has ILS with facial changes intermediate between
typical ILS and MDS (C) and LIS grade 3 with a posterior 1 anterior gradient (D). LP82-002 (E and F) and LR01-167 (G and H) have consensus
MDS (E and G) and severe LIS grade 1 (F and H) with no visible gradient. Both the brain and face abnormalities are more severe than in the
patients with ILS shown (A–D). Normal T1 and T2 axial images are shown for comparison (I and J). The face and brain abnormalities are
more subtle in subjects with deletions that do not include the LIS1 gene. DR01-001 has a mildly dysmorphic facial appearance not specific for
MDS (K) and mild frontal lobe hypoplasia without LIS (L).
and DB, their telomeric breakpoints are respectively
localized between the SREC (GenBank XM_008489)
and PITPNa (GenBank NM_006224) genes close to
D17S1577 and between the MYO1C (GenBank XM_
028385) and CRK genes (figs. 2 and 5). Finally, deletions
in hybrids CA2 and KCB4 probably have the same telo-
meric boundary, which is localized around D17S1582,
shown by amplification of only the ABR gene (NM_
021962 and NM_001092) for both patients (figs. 2 and
5). In addition, for KCB4, we confirmed the partial de-
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Figure 2 Physical and transcriptional map of the interval from D17S1845 to the telomere. A, The chromosomal orientation of the BAC/
PAC contig covering the most distal 2.8 Mb of chromosome 17 in the region p13.3 is indicated. STS markers, genes, and BAC ends used for
mapping are depicted by vertical lines at the top of the figure. A gray or red circle signifies the presence of an STS, a gene, or a BAC end on
an individual PAC or BAC clone. All PAC clones are underlined, and BAC clones used in FISH analysis are indicated in red. The broken line
indicates the gap between the main contig and the telomeric minicontig. Known genes mapped previously in this region are noted in blue, and
the direction of transcription is indicated by an arrow. A pseudogene is denoted by a black box. The cDNA clones corresponding to unknown
genes are noted in green. All known and new genes are placed exactly below the genomic clones that contain them. B, Schematic representation
of deletions of the 17p13.3 region identified in patients with ILS, MDS, or other phenotypes without LIS. The solid lines below the map represent
nondeleted genomic BAC/PAC clones. The dotted lines represent deletions associated with the patient number listed above. For patients with
ILS or MDS, the dashed line indicates the largest deletion identified in each group of patients. The telomeric boundaries of 17p13.3 deletion
of hybrids SG2, BR8, DB, CA2, and KCB4 are indicated by orange circles.
letion of the LIS1 gene by no amplification of exon 2
(data not shown). Thus, in patients defined as having
an MDS phenotype with the most severe LIS grade (CA2
and KCB4), we found exclusive deletion of only two
genes (CRK and 14-3-3) that were not deleted in ILS
patients (SG2, BR8, and DB) (fig. 5).
Discussion
Several syndromes—such as Williams syndrome (del
7q11), Prader-Willi and Angelman syndromes (del
15q11-q13), and DiGeorge syndrome (del 22q11)—are
associated with hemizygous deletions at recurrent sites
of a specific chromosome (Morrow et al. 1995; Osborne
et al. 1997; Christian et al. 1999). These are classical
contiguous gene-deletion syndromes, in which the in-
activation of several unrelated genes is involved in pro-
ducing a complex phenotype. MDS has long been rec-
ognized as a contiguous gene-deletion syndrome with
variable breakpoints, but the relationship between the
genes deleted within chromosome 17p13.3 and theMDS
phenotype has never been elucidated. By mapping the
extent of deletions of the 17p13.3 region, which result
in either ILS orMDS, we previously described a common
critical region containing the LIS1 gene responsible for
both disorders (Chong et al. 1997). Our previous data
also suggested that considerable overlap exists between
the deleted region in patients with ILS and MDS, with
the deletion in patients with MDS extending more telo-
meric on 17p13.3 (Ledbetter et al. 1989; Chong et al.
1997).
We have previously shown a relationship between ge-
notype and phenotype in a large number of patients
with ILS secondary to intragenic LIS1 abnormalities,
revealing a correlation between LIS severity and the lo-
cation and type of LIS1 mutation (Cardoso et al. 2000;
Leventer et al. 2001). In that group of patients—even
in those with a completely deleted or nonfunctional
LIS1 gene—there were areas of simplified brain folds
(pachygyria), rather than completely absent folds (agy-
ria), as seen only in patients with MDS. There has never
been an adequate explanation as to why patients with
MDS have the most severe LIS phenotype. One hy-
pothesis is that they are hemizygous for one or more
genes, other than LIS1, that are involved in cortical
development. To address this question, we initially con-
structed a detailed physical and transcriptional map of
the 17p13.3 region. Next, we used this map to compare
and contrast the boundaries of the deletions in a large
number of patients with ILS and MDS. In addition, we
studied four patients with terminal deletions involving
17p13.3 but without LIS. As hypothesized, we have
shown that patients with MDS have a larger telomeric
deletion than patients with ILS, and the larger deletions
show a more severe grade of LIS. We have also shown
that a deletion from ABR, toward the telomeric end of
chromosome 17p, is associated with no apparent phe-
notype. These data proved very helpful in allowing us
to define the distal boundary of the telomeric MDS crit-
ical region. We were able to narrow this region to 400
kb by comparing the deletions in ILS andMDS patients.
In this interval we identified eight genes deleted exclu-
sively in patients with MDS. These data clearly suggest
that genes other than LIS1 may participate in producing
the MDS phenotype and support for the first time the
concept that MDS truly is a contiguous gene-deletion
syndrome.
The identification of eight genes (PRP8, RILP, SREC,
PITPNa, SKIP, MYO1C, CRK, and 14-3-3) in our
newly defined telomeric MDS critical region is a first
step in our goal to characterize which additional genes
distal toLIS1may be responsible for the clinical features
that distinguish MDS from ILS. Existing functional in-
formation regarding the proteins encoded by these genes
show that PRP8 is a highly conserved spliceosomal pro-
tein, which provides important catalytic and regulatory
functions for pre-mRNA processing (Kuhn et al. 1999).
Rab7-interacting lysosomal protein (or RILP) controls
lysosomal transport by inducing the recruitment of
functional dynein-dynactin motor complexes (Jordens
et al. 2001). The scavenger receptor expressed by en-
dothelial cells (or SREC) mediates the selective uptake
of modified low-density lipoprotein (LDL) such as acet-
ylated-LDL and oxidized-LDL into endothelial cells
(Adachi et al. 2002). Phosphatidylinositol transfer pro-
tein alpha (PITPNa) is a member of a diverse set of
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Figure 4 Three-color FISH analysis showing the variability of the deletions of the 17p13.3 region. Three probes—PAC95H6 (red),
BAC818O24 (green), and BAC68F18 (magenta)—from the 17p subtelomeric region were used in these FISH experiments to size the deletion
of the 17p13.3 region in various patients (B, C, and D) compared with a normal control (A). B, FISH on patient (LP99-086) who has ILS (fig.
1C and 1D) showed the absence of PAC95H6 in red (containing the LIS1 gene). C, In patient LR01-167, who has MDS (fig. 1G and 1H),
there is absence of signal of all three probes on one chromosome 17. D, Patient DR01-001 does not have all typical MDS facial features or
LIS, but does have an abnormal brain MRI (frontal lobe hypoplasia and partial agenesis of the corpus callosum) (fig. 1K and 1L). Her FISH
study shows the presence of PAC95H6 on both chromosome 17s and absence of the probes BAC818O24 and BAC68F18 from one chromosome
17.
cytosolic phospholipid transfer proteins that are distin-
guished by their ability to regulate the interface between
signal transduction, membrane-trafficking, and lipid
metabolic pathways in eukaryotic cells (Liscovitch and
Cantley 1995). SKIP (Ski-interacting protein) is a part-
ner of the oculopharyngeal muscular dystrophy gene
PABP2 and stimulates directly or indirectly muscle-spe-
cific gene expression (Kim et al. 2001). MYO1C is a
motor protein and participates in the slow component
of adaptation by hair cells, which are the sensory cells
of the inner ear (Holt et al. 2002). The CRK gene exists
in two splice variants, CRK I (28 kDa) and CRK II (42
kDa), of which CRK II encodes an additional N-ter-
minal SH3 domain (Reichman et al. 1992). The product
of CRK is an adaptator signaling protein that is mostly
composed of SH2 and SH3 domains, and has been
shown to play a pivotal role in cell proliferation, dif-
ferentiation, and migration (Feller et al. 1998). The 14-
3-3 protein is a member of a large family of signaling
molecules defined as discrete phosphoserine/threonine
binding modules. The 14-3-3 family of proteins play
critical roles in cell signaling events that control progress
through the cell cycle, transcriptional alterations in re-
sponse to environmental cues, and programmed cell
death (Yaffe et al. 2002).
On the basis of this functional data, many of these
genes may be considered good candidates to be involved
in the more severe phenotype seen in patients withMDS.
Our PCR mapping results of somatic cell hybrids from
patients with MDS who have interstitial deletions has
allowed us to further reduce the number of candidate
genes likely to be involved in the brain phenotypeMDS.
When we compared the severity of LIS in the patients
in this study, only those with MDS had complete agyria
(grade 1). We know from previous studies that deletion
of LIS1 alone is not sufficient to cause this severe form
of LIS (Cardoso et al. 2000). The patients in our study
with complete agyria uniformly had the largest deletions
(fig. 3). Gene-by-gene mapping of these deletions in se-
lected patients by PCR showed that two genes (CRK
and 14-3-3) were exclusively deleted only in those pa-
tients with the most severe form of LIS (fig. 5). Thus,
we conclude that deletion of one or both of these genes
in addition to LIS1 may contribute to the severe LIS
phenotype seen only in MDS. To take this hypothesis
further, it must then be assumed that one of these genes
has a role in cortical development and specifically in
neuronal migration.
The 14-3-3 gene product is probably the best can-
didate, on the basis of a mouse knock-out phenotype
that supports a role for 14-3-3 in cortical development
(K. Toyo-oka, A. Shionoya, M. J. Gambello, C. Car-
doso, R. J. Leventer, H. L. Ward, R. Ayala, L. H. Tsai,
W. B. Dobyns, D. H. Ledbetter, S. Hirotsune, and A.
Boris-Wynshaw, unpublished data). As in human, het-
erozygous loss of both Lis1 and 14-3-3 result in more
severe cortical and hippocampal developmental defects
(Hirotsune et al. 1998; Toyo-oka et al., unpublished
data). Thus, the phenotypes in both human and mouse
support the hypothesis that 14-3-3 is a gene that may
contribute to the severe migration defects seen in pa-
tients with MDS. CRK should also be considered as a
candidate to participate in the LIS phenotype seen in
MDS. It has been shown that CRK may have a role in
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Figure 5 Extent of deletion in the telomeric MDS critical region. PCR analysis was performed on somatic cell hybrid cell lines derived
from lymphoblasts of three patients with ILS—SG2 (LP90-017), BR8 (LP87-001), and DB (LP86-003)—and from two patients withMDS—CA2
(LP82-002) and KCB4 (LP84-001)—whose deletion breakpoints have been characterized by FISH analysis. Primers used specially amplified all
10 human genes (see the “Subjects and Methods” section) that extend from the centromere (SERPINF1) to telomere (ABR) that are present
within the telomeric MDS critical region. DNAs from hamster, mouse, and human were used in these experiments to show the specificity of
the primers.
cell proliferation and migration by regulating the con-
nection between integrins and the cellular cytoskeleton
in areas named “focal adhesion” (Tsuda et al. 2002).
However, even if CRK is involved in cell growth and
motility, there is no evidence as yet that haploinsuffi-
ciency of this gene can cause a brain anomaly, and the
creation of a mouse knockout of the CRK gene is re-
quired. In view of the lack of functional information
on the CRK gene, and evidence that 14-3-3 is involved
in brain development, we propose that, of these two
genes, 14-3-3 is the better candidate for the more se-
vere LIS phenotype seen in patients with MDS com-
pared with patients with ILS.
In conclusion, we propose that MDS is truly a con-
tiguous gene-deletion syndrome, caused by haploinsuf-
ficiency of at least nine critical genes, including LIS1,
that contribute to the facial and brain phenotype seen
in patients with MDS. Furthermore, we suggest that the
deletion of 14-3-3 and/or CRK in addition to LIS1 is
the factor responsible for the most severe form of clas-
sical LIS seen only in patients with MDS.
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